Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
levo
Press Release
Jan 18, 2022
Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
Read More
Press Release
Jul 6, 2021
FDA Grants Priority Review for Levo Therapeutics' New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
Read More
Press Release
Nov 18, 2019
Levo Therapeutics Receives Fast Track Designation From FDA for Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
Announces Completion of Series B Financing
Read More
Press Release
Dec 12, 2018
Levo Therapeutics Announces Initiation of the CARE-PWS Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
Read More
Press Release
Jun 21, 2018
Levo Therapeutics Announces Publication of Phase 2 Study Results and Planned Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
Read More
First
Prev
1
Next
Last